KEAP1 and colitis: More recent investigations conducted both in vivo (by DSS-induced colitis as an experimental model of IBD) and in vitro (by colonic cells NCM460) revealed that CPUY192018, an inhibitor of the Keap1–Nrf2 interaction, reduced the expression of inflammatory cytokines and exerted a cytoprotective effect.